The interim nash results weren't great. The company refocused the SH enthusiasm by re-explaining the endpoint targets that did not include a reduction in fatty liver. Dont get me
wrong, i think there will be some good data from the results but not in tbe fatty liver area.
Efficacy was the focus.
Cheers
My Predictions, page-3
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.79M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $16.01K | 159.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5161 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 172982 | 6 |
View Market Depth
| Last trade - 14.17pm 17/07/2024 (20 minute delay) ? |
| IMC (ASX) Chart |